- Home
- FOSL vs AGEN Comparison
FOSL vs AGEN Comparison
Compare FOSL & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOSL
- AGEN
- Stock Information
- Founded
- FOSL 1984
- AGEN 1994
- Country
- FOSL United States
- AGEN United States
- Employees
- FOSL N/A
- AGEN N/A
- Industry
- FOSL Consumer Specialties
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FOSL Consumer Discretionary
- AGEN Health Care
- Exchange
- FOSL Nasdaq
- AGEN Nasdaq
- Market Cap
- FOSL 100.0M
- AGEN 87.7M
- IPO Year
- FOSL 1993
- AGEN 2000
- Fundamental
- Price
- FOSL $1.66
- AGEN $6.69
- Analyst Decision
- FOSL Strong Buy
- AGEN Buy
- Analyst Count
- FOSL 1
- AGEN 4
- Target Price
- FOSL $5.00
- AGEN $13.00
- AVG Volume (30 Days)
- FOSL 214.2K
- AGEN 1.4M
- Earning Date
- FOSL 08-07-2025
- AGEN 08-07-2025
- Dividend Yield
- FOSL N/A
- AGEN N/A
- EPS Growth
- FOSL N/A
- AGEN N/A
- EPS
- FOSL N/A
- AGEN N/A
- Revenue
- FOSL $1,123,399,000.00
- AGEN $99,524,000.00
- Revenue This Year
- FOSL N/A
- AGEN $12.69
- Revenue Next Year
- FOSL N/A
- AGEN N/A
- P/E Ratio
- FOSL N/A
- AGEN N/A
- Revenue Growth
- FOSL N/A
- AGEN N/A
- 52 Week Low
- FOSL $0.86
- AGEN $1.38
- 52 Week High
- FOSL $2.61
- AGEN $18.74
- Technical
- Relative Strength Index (RSI)
- FOSL 59.43
- AGEN 63.27
- Support Level
- FOSL $1.55
- AGEN $4.78
- Resistance Level
- FOSL $1.80
- AGEN $7.34
- Average True Range (ATR)
- FOSL 0.11
- AGEN 0.64
- MACD
- FOSL 0.02
- AGEN 0.13
- Stochastic Oscillator
- FOSL 72.00
- AGEN 75.33
About FOSL Fossil Group Inc.
Fossil Group Inc is a design, innovation and distribution company in consumer fashion accessories. The products include traditional watches, smartwatches, jewelry, handbags, small leather goods, belts and sunglasses. The reportable segments are comprised of 1) Americas segment includes sales in Canada, Latin America and the United States. 2) Europe segment includes sales in European countries, the Middle East and Africa. 3) Asia segment includes sales in Australia, China, India, Indonesia, Japan, Malaysia, New Zealand, Singapore, South Korea and Thailand. Each reportable operating segment includes sales to wholesale and distributor customers, and sales through Company-owned retail stores and e-commerce activities based on the location of the selling entity.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).